MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative,foreig report with the FDA on 2020-02-24 for ORBERA? INTRAGASTRIC BALLOON SYSTEM B-50000 manufactured by Apollo Endosurgery, Inc..
[186735447]
Initial medwatch sent to the fda. A review of the device labeling notes the following: the risk documentation for this device establishes the occurrence ranking for the reported event "inflation" as "remote", which is defined by apollo as. 02% -. 49% of complaints over units sold. A review for the intragastric balloon products for the failure mode "inflation" is performed during quarterly complaint analysis meetings (cam) and has demonstrated that global balloon inflation rate remains at "remote". Therefore, apollo determined that the reported event is occurring within the range of the expected frequency and severity for this reported event, as referenced in the cam meeting slides. The current orbera? Intragastric balloon system directions for use (dfu) addresses the known and anticipated potential events of "pain ", "vomiting", and "nausea" as follows: "the physiological response of the patient to the presence of the orbera system balloon may vary depending upon the patient's general condition and the level and type of activity. The types and frequency of administration of drugs or diet supplements and the overall diet of the patient may also affect the response. " "each patient must be monitored closely during the entire term of treatment in order to detect the development of possible complications. Each patient should be instructed regarding symptoms of deflation, gastrointestinal obstruction, ulceration and other complications which might occur, and should be advised to contact his/her physician immediately upon the onset of such symptoms. " "complications: possible complications of the use of the orbera system include: gastric discomfort, feelings of nausea and vomiting following balloon placement as the digestive system adjusts to the presence of the balloon. Continuing nausea and vomiting. This could result from direct irritation of the lining of the stomach or as a result of the balloon blocking the outlet of the stomach. It is even theoretically possible that the balloon could prevent vomiting (not nausea or retching) by blocking the inlet to the stomach from the esophagus. Abdominal or back pain, either steady or cyclic. "
Patient Sequence No: 1, Text Type: N, H10
[186735448]
Reported as: "the patient complains of severe abdominal pain and vomiting. An x-ray was performed and noted balloon hyperinflation. "
Patient Sequence No: 1, Text Type: D, B5
Report Number | 3006722112-2020-00026 |
MDR Report Key | 9747069 |
Report Source | COMPANY REPRESENTATIVE,FOREIG |
Date Received | 2020-02-24 |
Date of Report | 2020-01-28 |
Date of Event | 2019-12-07 |
Date Mfgr Received | 2020-01-28 |
Device Manufacturer Date | 2018-04-18 |
Date Added to Maude | 2020-02-24 |
Event Key | 0 |
Report Source Code | Manufacturer report |
Manufacturer Link | Y |
Number of Patients in Event | 0 |
Adverse Event Flag | 3 |
Product Problem Flag | 3 |
Reprocessed and Reused Flag | 3 |
Health Professional | 3 |
Initial Report to FDA | 3 |
Report to FDA | 3 |
Event Location | 3 |
Manufacturer Contact | DR. DAVID HOOPER |
Manufacturer Street | 1120 S. CAPITAL OF TEXAS HWY BLDG 1, STE. 300 |
Manufacturer City | AUSTIN, TX |
Manufacturer Country | US |
Manufacturer G1 | APOLLO ENDOSURGERY COSTA RICA, SRL |
Manufacturer Street | COYOL FREE ZONE BUILDING B 13.3 |
Manufacturer City | ALAJUELA, CS |
Manufacturer Country | CS |
Single Use | 3 |
Previous Use Code | 3 |
Event Type | 3 |
Type of Report | 3 |
Brand Name | ORBERA? INTRAGASTRIC BALLOON SYSTEM |
Generic Name | INTRAGASTRIC BALLOON |
Product Code | LTI |
Date Received | 2020-02-24 |
Model Number | B-50000 |
Catalog Number | B-50000 |
Lot Number | AF01833 |
Operator | HEALTH PROFESSIONAL |
Device Availability | N |
Device Eval'ed by Mfgr | R |
Device Sequence No | 1 |
Device Event Key | 0 |
Manufacturer | APOLLO ENDOSURGERY, INC. |
Manufacturer Address | 1120 S. CAPITAL OF TEXAS HWY BLDG 1, STE. 300 AUSTIN, TX US |
Patient Number | Treatment | Outcome | Date |
---|---|---|---|
1 | 0 | 1. Required No Informationntervention | 2020-02-24 |